BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew Sells 404 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby J. Mathew sold 404 shares of the company’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $10,916.08. Following the sale, the executive vice president now owns 262,715 shares of the company’s stock, valued at $7,098,559.30. This trade represents a 0.15 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

BioLife Solutions Price Performance

BioLife Solutions stock opened at $27.69 on Thursday. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The firm’s 50-day simple moving average is $25.91 and its 200 day simple moving average is $24.27. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The firm has a market capitalization of $1.28 billion, a PE ratio of -26.12 and a beta of 1.92.

Analysts Set New Price Targets

Several equities analysts have issued reports on BLFS shares. TD Cowen boosted their price objective on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Northland Securities boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research note on Wednesday. HC Wainwright reduced their price objective on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Monday, November 18th. KeyCorp boosted their target price on BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Finally, Craig Hallum increased their target price on BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.43.

Institutional Trading of BioLife Solutions

Several institutional investors and hedge funds have recently modified their holdings of the business. Mark Sheptoff Financial Planning LLC purchased a new position in shares of BioLife Solutions during the 3rd quarter worth approximately $28,000. Quest Partners LLC purchased a new position in BioLife Solutions during the third quarter worth $57,000. GAMMA Investing LLC raised its holdings in shares of BioLife Solutions by 29.4% in the third quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock worth $83,000 after acquiring an additional 748 shares during the last quarter. Canada Pension Plan Investment Board purchased a new stake in shares of BioLife Solutions in the second quarter valued at $122,000. Finally, Arizona State Retirement System acquired a new stake in shares of BioLife Solutions during the second quarter valued at $217,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.